{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
KALA BIO, Inc.
KALA BIO, Inc. Hits New 52-Week High of $20.60
KALA BIO, Inc. has achieved a new 52-week high, reflecting significant growth over the past year. The company has outperformed the S&P 500 and boasts a notable return on equity, despite being unprofitable. With a market capitalization of USD 102 million, it maintains a balanced capital structure.
KALA BIO, Inc. Hits New 52-Week High of $20.12, Up 195% Year-Over-Year
KALA BIO, Inc. has achieved a new 52-week high of USD 20.12, reflecting a substantial increase in stock performance over the past year. With a market capitalization of USD 102 million, the company operates in the Pharmaceuticals & Biotechnology sector and has demonstrated remarkable profitability metrics despite currently being loss-making.
KALA BIO, Inc. Hits New 52-Week High of $19.69
KALA BIO, Inc. has achieved a new 52-week high, reflecting significant growth from its previous low. The company has seen a remarkable one-year gain, outpacing broader market performance. Despite being unprofitable, it showcases an extraordinary return on equity, while its financial metrics indicate a focus on growth over dividends.
Is KALA BIO, Inc. overvalued or undervalued?
As of August 4, 2023, KALA BIO, Inc. is considered overvalued and has deteriorated to a "does not qualify" rating due to poor financial metrics, including a Price to Book Value of 4.68 and a ROE of -617.36%, significantly underperforming its peers and the S&P 500.
Is KALA BIO, Inc. technically bullish or bearish?
As of May 19, 2025, KALA BIO, Inc. is in a mildly bearish trend due to daily moving averages, despite some mildly bullish indicators from the weekly MACD and KST, leading to a cautious outlook overall.
Who are in the management team of KALA BIO, Inc.?
As of March 2022, KALA BIO, Inc.'s management team includes Mr. Mark Iwicki as Chairman, President, and CEO, with Mr. Andrew Koven as Lead Independent Director and independent directors Dr. Gregory Grunberg, Mr. Robert Paull, Mr. Gregory Perry, and Mr. Howard Rosen.
What does KALA BIO, Inc. do?
KALA BIO, Inc. is a biopharmaceutical company specializing in developing therapeutics for eye diseases using its nanoparticle-based technology. It has a market cap of approximately $26.97 million and reported a net profit loss of $9 million as of March 2025.
How big is KALA BIO, Inc.?
As of Jun 18, KALA BIO, Inc. has a market capitalization of 26.97 million and reported net sales of 0.00 million with a net profit of -35.66 million over the last four quarters. Shareholder's funds are 12.33 million, and total assets amount to 55.48 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
